MedPath

INTESTINAL MICRO-ORGANISMS IN THE PATHOGENESIS OF NASH AND THE ROLE OF MODULATION OF ENTERIC BACTERIA IN TREATMENT. - Enteric bacteria and non alcoholic steatohepatitis

Conditions
on alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH)
Registration Number
EUCTR2006-001774-24-GB
Lead Sponsor
ewcastle u Tyne Hospitals NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
40
Inclusion Criteria

The presence of fatty liver or steatohepatitis on liver biopsy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Only stable out-patients on regular follow up will be considered. All others will be excluded.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath